In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. - Wikidata - wikimedia - TriplyDB

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

http://www.wikidata.org/entity/Q41858315

about

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro Absolute oral bioavailability of ciprofloxacin Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.Genomewide screen for modulators of evolvability under toxic antibiotic exposure.Is Ciprofloxacin a Substrate of P-glycoprotein?In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans.Mechanisms of antibiotic resistance in Campylobacter species.Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin.Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections Relationships between renal function and disposition of oral ciprofloxacin Pharmacokinetics of ciprofloxacin after oral and parenteral administration.Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.Ciprofloxacin penetration into extravascular spaces in a rabbit model.Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography.Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.In vitro activity of ciprofloxacin combined with azlocillin.Tissue penetration of ciprofloxacin after single and multiple doses.Ciprofloxacin in the treatment of pneumonia.Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

P2860

Q24670241-188130EB-ED80-44B6-B21A-DF98C09F0796 Q24685241-AA83D2B8-2ADB-4A17-91BC-9906D2D6E33A Q28361123-EF22562E-5151-42CE-874E-DACAE83192B6 Q28361860-25D9C865-E617-4208-823A-056AA938B5C9 Q30451758-D4DA58E2-3309-429F-864E-F56863CA8F3B Q33668223-7835D556-3AB6-4667-A996-3AFCD26F7A0A Q33740530-CF6A338C-115A-4CC4-A9EC-6837784429DD Q33753240-102CFFBE-9DC3-41C1-8C8B-63FA4861979F Q34622742-D1E509D6-1C41-453C-9252-A7CB2C4724D3 Q34719336-E5A94E23-2F1F-49D6-96FD-8D16ACA7EB10 Q34886134-166A7B9E-86FA-48B3-B67A-3D756F7E54CE Q35243584-C628271E-215F-45B1-9C7E-4FEABC13BC0C Q35243644-580356AE-01B5-4BAD-B437-D90AC6782BCC Q35250004-CBEE47E9-DE3F-4B28-9347-5D5233B9F077 Q35315833-9F28AD03-559E-42EA-B25B-68CB1CD6143F Q35346446-3125CAC5-2B99-45E3-A28C-932B9845066D Q35536186-DAD4C117-54AB-4092-BB75-75ABDDDBAF20 Q35539176-897B4153-4B42-4012-85DA-843B016869C1 Q35539396-E01BA8C1-633E-40A0-A275-27AC1C95042B Q35542198-A074CB52-94E4-41EA-8159-FDD8157DC5D7 Q35563727-4CD6F795-1027-4C12-B013-EC44E3DACD40 Q35564482-C46A69B2-A21B-469E-BDC6-8B34B45B6903 Q35570646-22FA100F-3D6C-4684-9666-FEDAA174BA10 Q35572334-3A4FDFA0-30E8-43A4-8A04-1BACE077C0DA Q35640867-F1480A26-8914-44F8-8185-BF8E692B2529 Q35641275-1319E21B-82DA-4553-AE01-7090F23AA5E3 Q35642422-9220F871-1829-47DC-A929-8B5F50A3AEED Q35646442-B7124B89-A9C4-4D32-B76C-29434D34B72C Q35648175-A89A9AF3-E22B-4A30-AF4B-9ACD1A832856 Q35649002-7E8F1F7C-7085-42B8-9A41-B4B49D273C41 Q35650590-39CD2251-D8B2-425E-867E-C4B3A288A4F8 Q35650708-FB0074ED-528A-4FC0-989E-CBB000339F7D Q35651376-0F1DE145-E05B-41C5-A887-9D731E156B25 Q35651395-19E7D1CF-2BEA-413A-9350-7F84F8905D4D Q35653503-33CF29BB-F7C8-48A3-8C6A-9B34B3B794C1 Q35653930-44A544B6-3F36-4C0D-9A81-5A742751BA63 Q35809707-AC1F9EEC-DD21-4F0D-9CEC-63E8F84D36C3 Q35814807-29FF4956-9E56-49D0-96BF-5148779F38F5 Q35846320-23A9CD9F-EA79-4030-9997-BE4059299166 Q35867101-8AE14B82-EDAA-4FFB-82B6-B7C35C79F3EC

P2860

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

http://www.wikidata.org/entity/Q41858315

description

1984 nî lūn-bûn

@nan

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

1984年论文

@zh

1984年论文

@zh-cn

name

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

@en

type

label

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

@en

prefLabel

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

@en

P1433

Q41858315-A47DBBD7-44E8-49F9-A5FF-3F2EC4B1CDEA

P1476

Q41858315-088EB6A2-FAE3-4830-9ACC-F21C43A9A9F6

P2093

Q41858315-8A392735-0B9F-4E5C-8FED-DF10606B9AD4

Q41858315-AC9C7159-2AC9-42CC-AA4A-8B910A2958F4

Q41858315-FF5AF4FA-4083-4634-AE1C-3A25C29F8523

P2860

Q41858315-00E5BD44-D59F-4AC9-9B82-65E37207D567

Q41858315-06447169-7A1F-48C3-8F6C-571A6DA62655

Q41858315-51331412-ACA9-4B22-AE97-2075518FBC43

Q41858315-513713AC-40C5-4FBC-8D03-3AB914F514D0

Q41858315-56D29470-BE95-4E9E-BFBA-9876A5C83E4B

Q41858315-5D7A4BF7-80ED-417A-8FD1-716135F68AC3

Q41858315-6C6490EE-59CE-4494-9CFA-554761EBBF0B

Q41858315-7954AF35-C1C7-4C03-8EA7-BD9163A1B4FA

Q41858315-9E57D7EA-6DCE-444B-87AB-785539090372

Q41858315-AD9A17C9-B36D-4220-B0D1-4F1B5915AEAE

P304

Q41858315-7A2A1CF9-3109-4F96-A568-62BDB01D6E79

P31

Q41858315-2CE59186-E41F-4452-8FF6-D8F3E9F0B6E4

P356

Q41858315-05AB0229-1D92-43F5-834A-5BF7F3E96DD6

P407

Q41858315-207591DE-12FB-45A7-93D9-E4E589947B63

P433

Q41858315-341F1AFC-2B8F-4B92-BCD8-005230D27626

P478

Q41858315-BB53CC0A-B1F3-4B00-92CA-8FE2E83C49D6

P577

Q41858315-87376AAA-D462-4BB9-83BC-91B526A8C5E0

P698

Q41858315-1BA96ABE-68BE-4CBE-9A6E-96D1D409D72D

P932

Q41858315-52A9A2A6-D4B8-4C10-8650-BF2399FA373D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

@en

P2093

Eliopoulos GM

http://www.w3.org/2001/XMLSchema#string

Gardella A

http://www.w3.org/2001/XMLSchema#string

Moellering RC Jr

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

In vitro and in vivo activity of DL-8280, a new oxazine derivative

Method of reliable determination of minimal lethal antibiotic concentrations.

Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.

Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns

In vitro antibacterial activity of norfloxacin (MK-0366).

In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.

P304

331-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.25.3.331

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

1984-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6721464

http://www.w3.org/2001/XMLSchema#string

P932

185510

http://www.w3.org/2001/XMLSchema#string